HIGHLIGHTS
- who: Yoshimitsu Wada from the Background Relugolix, an oral gonadotrophin-releasing hormone receptor antagonist, was launched in Japan have published the paper: Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study, in the Journal: (JOURNAL)
- what: There is only one case report described a patient treated for a with who developed severe However it remains unclear which characteristics of leiomyomas can lead to severe Thus the aim of this study was to investigate the characteristics of leiomyomas that would cause severe when treated with Methods The study demonstrated that in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.